Abstract
Treatment of advanced hepatocellular carcinoma (HCC) remains challenging, particularly with the limited systemic therapy options. Sorafenib remains the only approved, targeted molecule for the treatment of advanced HCC. Although a survival benefit was demonstrated with sorafenib, it remains only true in the population of patients with Child-Turcotte-Pugh class A disease. Sorafenib also has distinct side effects that require close monitoring. Newer tyrosine kinase inhibitors and angiogenic inhibitors have been evaluated with disappointing results, particularly in phase III trials. Herein we review the pertinent trials for targeted therapy in HCC to date.
Keywords:
Hepatocellular carcinoma; Systemic therapy; Targeted agents.
Copyright © 2015 Elsevier Inc. All rights reserved.
MeSH terms
-
Alanine / analogs & derivatives
-
Alanine / therapeutic use
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / therapy
-
Chemoembolization, Therapeutic*
-
Combined Modality Therapy
-
Hepatectomy
-
Humans
-
Indoles / therapeutic use
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / therapy
-
Liver Transplantation / methods
-
Niacinamide / analogs & derivatives*
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / therapeutic use*
-
Preoperative Care
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors
-
Pyrroles / therapeutic use
-
Signal Transduction
-
Sorafenib
-
Sunitinib
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
Triazines / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Indoles
-
Phenylurea Compounds
-
Pyrroles
-
Triazines
-
Niacinamide
-
Sorafenib
-
brivanib
-
Proto-Oncogene Proteins c-met
-
TOR Serine-Threonine Kinases
-
Alanine
-
Sunitinib